Clinical Trial Update: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer [Phase 1]

View source ↗

Summary

Seagen's SEA-TGT (SGN-TGT) Phase 1 safety study in advanced cancers has been terminated. The study enrolled patients across multiple cancer types, including non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Cutaneous Melanoma
• Diffuse Large B-cell Lymphoma
• Gastric Carcinoma
• Gastroesophageal Junction Carcinoma
• Head and Neck Squamous Cell Carcinoma
• Non-small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• SEA-TGT (SGN-TGT)

Snippet

Sponsor: Seagen Inc. | Conditions: Non-small Cell Lung Cancer, Gastric Carcinoma | Phase 1 | Status: TERMINATED